Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma
1 competing product in clinical development for Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma.
Pipeline by Phase
Phase 11
All Products (1)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| mRNA-2752 + Durvalumab | AstraZeneca | Phase 1 | Completed | 29 |